| Literature DB >> 28847699 |
Ryan Navarro1, Rajeev Nair2, Andrea Peda2, Meiji Soe Aung3, G S Ashwinie4, Christa A Gallagher1, Yashpal S Malik5, Nobumichi Kobayashi3, Souvik Ghosh6.
Abstract
Although canine parvovirus (CPV) and canine enteric coronavirus (CCoV) are important enteric pathogens of dogs and have been studied extensively in different parts of the world, there are no reports on these viruses from the Caribbean region. During 2015-2016, a total of 104 diarrheic fecal samples were collected from puppies and adult dogs, with or without hemorrhagic gastroenteritis, on the Caribbean island of St. Kitts (KNA). By PCR, 25 (24%, n=104) samples tested positive for CPV. Based on analysis of the complete deduced VP2 amino acid sequences, 20 of the KNA CPV strains were assigned to new CPV-2a (also designated as CPV-2a-297A). On the other hand, the VP2 genes of the remaining 5 strains were partially characterized, or could not be sequenced. New CPV-2a was the predominant CPV variant in St. Kitts, contrasting the molecular epidemiology of CPV variants reported in most studies from nearby North and South American countries. By RT-PCR, CCoVs were detected in 5 samples (4.8%, n=104). Based on analysis of partial M-protein gene, the KNA CCoV strains were assigned to CCoV-I genotype, and were closely related to CCoV-I strains from Brazil. To our knowledge, this is the first report on detection and genetic diversity of CPV and CCoV in dogs from the Caribbean region, and underscores the importance of similar studies in the other Caribbean islands.Entities:
Keywords: CCoV-I; Canine enteric coronavirus; Canine parvovirus; Caribbean region; Genetic diversity; New CPV-2a
Mesh:
Substances:
Year: 2017 PMID: 28847699 PMCID: PMC7114545 DOI: 10.1016/j.virusres.2017.08.008
Source DB: PubMed Journal: Virus Res ISSN: 0168-1702 Impact factor: 3.303
Sampling dates, breed, age, and vaccination status of dogs that tested positive for canine parvovirus (CPV), or canine enteric coronavirus (CCoV) on the Caribbean island of St. Kitts (KNA). The GenBank accession numbers, and genotype nature of the CPV and CCoV strains are also shown.
| Virus | No. | Strain | Sampling date | Breed | Age | Variant | Vaccination status against CPV | Gene analyzed | GenBank accession no. |
|---|---|---|---|---|---|---|---|---|---|
| CPV | 1 | RVC6/KNA | Feb 2015 | Island mix | 1month 1 week | New CPV-2a | None | VP2, complete ORF | KY399033 |
| 2 | RVC11/KNA | June 2015 | Mixed breed | 3 months | New CPV−2a | None | VP2, complete ORF | KY399034 | |
| 3 | RVC15/KNA | June 2015 | Dachshund | 1 month 2weeks | – | None | Not sequenced | – | |
| 4 | PVC6/KNA | June 2015 | Pit bull | 6 months | New CPV−2a | Not available | VP2, complete ORF | KY399035 | |
| 5 | PVC8/KNA | June 2015 | Rottweiler x Mastiff | 5 months | New CPV−2a | Not available | VP2, complete ORF | KY399036 | |
| 6 | RVC17/KNA | July 2015 | Island mix | Adult | New CPV−2a | None | VP2, complete ORF | KY399037 | |
| 7 | RVC20/KNA | July 2015 | Island mix | 5 months | New CPV−2a | None | VP2, complete ORF | KY399038 | |
| 8 | RVC21/KNA | July 2015 | Island mix | 5 months | New CPV−2a | None | VP2, complete ORF | KY399039 | |
| 9 | PVC11a/KNA | July 2015 | Mastiff mix | 3 months | New CPV−2a | Not available | VP2, complete ORF | KY399040 | |
| 10 | PVC12/KNA | July 2015 | Island mix | 2 months | New CPV−2a | Not available | VP2, complete ORF | KY399041 | |
| 11 | PVC13/KNA | July 2015 | Island mix | 2 months | New CPV−2a | Not available | VP2, complete ORF | KY399042 | |
| 12 | RVC23/KNA | Aug 2015 | Mixed breed | 2 years | New CPV−2a | None | VP2, complete ORF | KY399043 | |
| 13 | RVC26/KNA | Aug 2015 | Mastiff mix | 6 months | New CPV−2a | None | VP2, complete ORF | KY399044 | |
| 14 | RVC43/KNA | Apr 2016 | Island mix | 1 month 3 weeks | New CPV−2a | 02−2016 | VP2, complete ORF | KY399045 | |
| 15 | RVC44/KNA | Apr 2016 | Island mix | 1 year | New CPV−2a | 06−2015, 07−2015 | VP2, complete ORF | KY399046 | |
| 16 | PVC18/KNA | Apr 2016 | Island mix | 1 year | − | Not available | VP2, partial ORF | KY399047 | |
| 17 | PVC21/KNA | Apr 2016 | Island mix | 3 years | − | Not available | VP2, partial ORF | KY399048 | |
| 18 | PVC28/KNA | May 2016 | Island mix | 1 year | – | Not available | Not sequenced | – | |
| 19 | RVC49/KNA | June 2016 | Mastiff mix | 2 months | New CPV−2a | None | VP2, complete ORF | KY399049 | |
| 20 | RVC50/KNA | June 2016 | Pit bull mix | 6 months | New CPV−2a | None | VP2, complete ORF | KY399050 | |
| 21 | RVC53/KNA | July 2016 | Rottweiler | 4 months 3 weeks | New CPV−2a | 05−2016 | VP2, complete ORF | KY933479 | |
| 22 | RVC54/KNA | July 2016 | Pit bull mix | 3 months | New CPV−2a | None | VP2, complete ORF | KY399051 | |
| 23 | RVC55/KNA | July 2016 | Island mix | 3 months | New CPV−2a | None | VP2, complete ORF | KY399052 | |
| 24 | RVC57/KNA | Aug 2016 | Island mix | 3 days | New CPV−2a | None | VP2, complete ORF | KY399053 | |
| 25 | RVC60/KNA | Aug 2016 | Mixed breed | 1 year 8 months | – | 12–2015 | Not sequenced | – | |
| CCoV | 1 | RVC5/KNA | Feb 2015 | Malinois | 1 year 5 months | CCoV-I | Not applicable | M, partial ORF | KY933480 |
| 2 | RVC 8/KNA | June 2015 | Mixed breed | 6 months | CCoV-I | Not applicable | M, partial ORF | KY399054 | |
| 3 | PVC5/KNA | June 2015 | Island mix | 3 months | CCoV-I | Not applicable | M, partial ORF | KY399055 | |
| 4 | PVC10/KNA | June 2015 | Pit bull | 1 month 1 week | CCoV-I | Not applicable | M, partial ORF | KY399056 | |
| 5 | RVC41/KNA | Feb 2016 | Mixed breed | 2 months 1 week | – | Not applicable | Not sequenced | – | |
Vaccination status against CPV at the time of collection of fecal sample.
Refers to a cross between a canine breed that is native to the island of St. Kitts, and another breed.
In a recent study, new CPV-2a has also been designated as CPV-2a-297A (Zhou et al., 2017).
ORF, Open Reading Frame.
Information on exact age not available.
Date/s (month-year) of vaccination with VANGUARD Plus 5 L4 (Zoetis, USA).
As only small amounts of fecal samples were received from the clinics, it was not possible to obtain the complete ORF sequence of VP2 gene. However, the partial deduced VP2 amino acid sequences of strains PVC18 and PVC21 exhibited 426-N and 555-V, seen in CPV-2a strains.
Comparison of evolutionary relevant amino acid (aa) residues of putative VP2 proteins of canine parvovirus (CPV) strains detected on the island of St. Kitts (KNA), Caribbean region, with those of CPV-2, CPV-2a, CPV-2b, CPV-2c, new CPV-2a, new CPV-2b, and vaccine strains. The KNA CPV strains are underlined. A dot ‘.’ indicates an identical amino acid residue at cognate position of deduced VP2 aa sequence of the concerned CPV strain with that of reference strain CPV-b/USA/1978. Alignment of complete deduced aa sequences of putative VP2 proteins of the CPV strains is shown in supplementary Fig. S2.
| Amino acid position | 80 | 87 | 93 | 101 | 103 | 232 | 267 | 297 | 300 | 305 | 321 | 323 | 324 | 375 | 426 | 440 | 555 | 560 | 564 | 568 | 570 | Variant |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strain | ||||||||||||||||||||||
| CPV-b/USA/1978 | R | M | N | I | A | I | F | S | A | D | N | N | Y | N | N | T | V | N | S | G | K | CPV-2 |
| CPV-15/USA/1984 | . | L | . | T | . | . | . | . | G | Y | . | . | . | D | N | . | I | . | . | . | . | CPV-2a |
| CPV-39/USA/1984 | . | L | . | T | . | . | . | . | G | Y | . | . | . | D | D | . | . | . | . | . | . | CPV-2b |
| 219/08-13/ITA/2008 | . | L | . | T | . | . | . | A | G | Y | . | . | . | D | E | . | . | . | . | . | . | CPV−2c |
| CPV-435/USA/2003 | . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a |
| Pome/KOR/2005 | . | L | . | T | . | . | . | A | D | Y | . | . | . | D | . | A | . | . | . | . | . | New CPV−2a |
| Uy-243/URY/2010 | . | L | . | T | . | . | Y | A | G | Y | . | . | I | D | . | A | . | . | . | . | . | New CPV−2a |
| CPV-436/USA/2003 | . | L | . | T | . | . | . | A | G | Y | . | . | . | D | D | . | . | . | . | . | . | New CPV−2b |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV−2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV-2a | |
| . | L | . | T | . | . | . | A | G | Y | . | . | . | D | . | . | . | . | . | . | . | New CPV-2a | |
| – | ||||||||||||||||||||||
| Vaccine VANGUARD | . | . | . | . | . | . | . | . | . | . | . | . | . | E | . | . | . | . | . | . | . | CPV-2 |
| Vaccine (Duramune) strain SAH | . | L | . | T | . | . | . | A | G | Y | K | . | . | D | D | . | . | . | . | . | E | New CPV−2b |
Positions of amino acid residues are based on those of CPV strain CPV-b/USA/1978.
The S297A mutation has been found to be fixed in VP2 of recent CPV-2a and CPV-2b strains, and these variants are sometimes designated as new CPV-2a and new CPV-2b strains (Decaro and Buonavoglia, 2012, Miranda and Thompson, 2016). In a recent study, new CPV-2a and new CPV-2b strains have also been designated as CPV-2a-297A and CPV-2b-297A, respectively (Zhou et al., 2017).
Amino Acid residue 426 of VP2 constitutes the sole basis of differentiating the new CPV-2a (426-N), new CPV-2b (426-D), and CPV-2c (426-E) strains (Decaro and Buonavoglia, 2012, Miranda and Thompson, 2016).
New CPV-2a strains exhibiting G300D are also referred to as CPV-2a-297A300D (Zhou et al., 2017).
Fig 1Phylogenetic analysis of the complete ORF nucleotide sequences of VP2 genes of St. Kitts (KNA) CPV strains with those of CPV-2, CPV-2a, CPV-2b, CPV-2c, new CPV−2a, new CPV-2b, and vaccine strains. Feline parvovirus (FPV) strain CU-4 clustered as the outgroup. The phylogenetic tree was created by the Maximum Likelihood (ML) method, and statistically supported by bootstrapping with 1000 replicates. Phylogenetic distances were measured by the Tamura-3-parameter model. The clustering patterns of KNA CPV strains were validated by constructing ML trees with other models, such as the Jukes–Cantor model, Kimura 2-parameter model, and Hasegawa–Kishino–Yano model (data not shown). In the tree, positions of the KNA CPV strains are highlighted with dark circles. GenBank accession numbers are shown in parentheses. Bootstrap values <70% are not shown. Scale bar, 0.005 substitutions per nucleotide.
Fig. 2Phylogenetic tree constructed by the Maximum Likelihood (ML) method from nucleotide sequences of partial M-protein encoding genes (369 bp) of the KNA CCoV strains with those of CCoV-I, CCoV-II, and feline coronavirus (FCoV) strains. The tree was statistically supported by bootstrapping with 1000 replicates, and phylogenetic distances were measured using the Tamura-3-parameter model of substitution. The clustering patterns of KNA CCoV strains were validated by creating ML trees with other mathematical models, such as the Jukes–Cantor model, Kimura 2-parameter model, and Hasegawa–Kishino–Yano model (data not shown). In the tree, the positions of the KNA CCoV strains are shown by dark circles. GenBank accession numbers are shown in parentheses. Bootstrap values <70% are not shown. Scale bar, 0.05 substitutions per nucleotide.